13811-11-5

Basic information

• Product Name: 3,5-diiodo-4-hydroxyphenylpropionic acid
• Synonyms: Hydrocinnamicacid, 4-hydroxy-3,5-diiodo- (6CI,7CI,8CI); Phloretic acid, 3,5-diiodo- (5CI);3,5-Diiodo-4-hydroxyphenylpropionic acid; 3,5-Diiodophloretic acid;3-(4-Hydroxy-3,5-diiodophenyl)propionic acid
• CAS NO: 13811-11-5
• Molecular Formula: C₉H₈I₂O₃
• Molecular Weight: 417.97
• Mol File: 13811-11-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 382°Cat760mmHg
• Flash Point: 184.8°C
• Appearance: /
• Density: 2.375g/cm³
• Vapor Pressure: 1.62E-06mmHg at 25°C
• Refractive Index: 1.722
• CAS DataBase Reference: 3,5-diiodo-4-hydroxyphenylpropionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-diiodo-4-hydroxyphenylpropionic acid(13811-11-5)
• EPA Substance Registry System: 3,5-diiodo-4-hydroxyphenylpropionic acid(13811-11-5)

Safety Data

• Hazardous Substances Data: 13811-11-5(Hazardous Substances Data)

Usage

Description

3,5-Diiodo-4-hydroxyphenylpropionic acid is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique molecular structure, which includes two iodine atoms and a hydroxyl group attached to a phenylpropionic acid backbone. 3,5-diiodo-4-hydroxyphenylpropionic acid plays a significant role in the development of medications targeting specific health conditions.

Uses

Used in Pharmaceutical Industry:
3,5-Diiodo-4-hydroxyphenylpropionic acid is used as an intermediate in the synthesis of 3,3’,5-Triiodo Thyropropionic Acid (T795410), which is a thyroid hormone analog. This hormone analog serves as an antilipemic, helping to regulate lipid levels in the body and potentially treating conditions related to high lipid levels, such as hyperlipidemia.
Additionally, given its role in the synthesis of thyroid hormone analogs, 3,5-diiodo-4-hydroxyphenylpropionic acid may also be utilized in the development of medications for other thyroid-related disorders, such as hypothyroidism or hyperthyroidism. Its specific application would depend on the requirements of the pharmaceutical compound being synthesized and the targeted health condition.

InChI:InChI=1/C9H8I2O3/c10-6-3-5(1-2-8(12)13)4-7(11)9(6)14/h3-4,14H,1-2H2,(H,12,13)

Upstream product

• 501-97-3 4-hydroxyphenylpropionic acid 

Downstream Products

• 189447-39-0 3-(4-hydroxy-3,5-diiodo-phenyl)-propionic acid ethyl ester 
• 53937-19-2 3-(p-hydroxy-m-iodo-phenyl)propionic acid 
• 39846-93-0 3-[4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid 
• 848915-24-2 3,5-diiododesaminotyrosyl-tyrosine ethyl ester 
• 264265-63-6 methyl 3-(4-hydroxy-3,5-diiodophenyl)propanoate 
• 1332500-05-6 methyl 3-(4-(2-ethylhexyloxy)-3,5-diiodophenyl)propanoate 
• 1332500-06-7 methyl 3-(3,5-diiodo-4-methoxyphenyl)propanoate 
• 1449075-85-7 4-hydroxyphenethyl 3-(4-hydroxy-3,5-diiodophenyl)-propanoate 
• 1221279-42-0 C₂₁H₂₀I₄O₆ 
• 110972-54-8 C₁₃H₁₁I₂NO₅ 

Relevant articles and documents

CARBONIC ANHYDRASE IX INHIBITOR CONJUGATES AND USES THEREOF

The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in imaging methods and cancer therapy.

N-substituted monomers and polymers

Biocompatible, bioresorbable polymers comprising a plurality of monomeric repeating units containing an amide group, wherein said amide groups are N-substituted and the N-substituent and degree of N-substitution are effective to lower the melt viscosity,

Radiopaque polymeric stents

Preferred embodiments of the present invention relate to polymeric medical devices, such as stents. More particularly, the polymeric compositions disclosed herein comprise halogen-containing, tyrosine-derived diphenols, optionally in conjunction with othe